Patents by Inventor Jayasree Vasudevan

Jayasree Vasudevan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Patent number: 7638648
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: December 29, 2009
    Assignee: Allergan Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li, Janet A. Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
    Patent number: 7468391
    Abstract: The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: December 23, 2008
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Rong Yang, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Roshantha A. Chandraratna
  • 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
    Patent number: 7351737
    Abstract: Compounds of the formula where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: April 1, 2008
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Yang-Dar Yuan, Roshantha A. Chandraratna
  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Publication number: 20080004455
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Application
    Filed: March 23, 2007
    Publication date: January 3, 2008
    Applicant: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha Chandraratna
  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Patent number: 7226951
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: June 5, 2007
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li, Janet A. Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
    Publication number: 20050187298
    Abstract: The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
    Type: Application
    Filed: December 13, 2004
    Publication date: August 25, 2005
    Applicant: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Rong Yang, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Roshantha Chandraratna
  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Publication number: 20050176689
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Application
    Filed: December 16, 2004
    Publication date: August 11, 2005
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha Chandraratna
  • 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY
    Publication number: 20050096380
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasing triglyceride levels and reducing serum thyroxine levels.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 5, 2005
    Inventors: Richard Beard, Tien Duong, Janet Takeuchi, Ling Li, Kwok Tsang, Xiaoxia Liu, Jayasree Vasudevan, Liming Wang, Santosh Sinha, Haiqing Yuan, Roshantha Chandraratna
  • 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6887896
    Abstract: Compounds of the formula where the variations have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasing triglyceride levels and reducing serum thyroxine levels.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: May 3, 2005
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, Janet A. Takeuchi, Ling Li, Kwok Yin Tsang, Xiaoxia Liu, Jayasree Vasudevan, Liming Wang, Santosh C. Sinha, Haiqing Yuan, Roshantha A. Chandraratna
  • Methods for identifying inhibitors of cytochrome P450RAI
    Patent number: 6855512
    Abstract: A method of identifying a compound which is an inhibitor of the enzyme cytochrome P450RAI is performed by selecting a compound that has retinoid activity in an art recognized assay and includes a benzoic acid, benzoic acid ester, naphthoic acid ester or heteroaryl carboxylic acid or ester moiety, with a partial structure of —A(R2)—(CH2)n—COOR8 where n is 0 and the remaining variables are as described in the specification and claims. Thereafter, a compound having the cytochrome P450RAI inhibitory activity is identified and selected where the compound has the —A(R2)—(CH2)2—COOR8 partial structure wherein the variable n is 1 or 2.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: February 15, 2005
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Liming Wang, Dehua Huang, Roshantha A. Chandraratna
  • 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6759546
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: July 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Richard L. Beard, Haiqing Yuan, Roshantha A. Chandratratna
  • 4-[(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL]-BENZOIC AND 2-[4-[(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL]-PHENYL]-ACETIC ACID, THEIR ESTERS AND SALTS HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY
    Patent number: 6740676
    Abstract: Compounds of Formula 1: wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: May 25, 2004
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Yang-Dar Yuan, Roshantha S. Chandraratna
  • Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
    Publication number: 20040077721
    Abstract: vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.
    Type: Application
    Filed: September 5, 2003
    Publication date: April 22, 2004
    Inventors: Yang-Dar Yuan, Jayasree Vasudevan, Scott Thacher, Roshantha A. Chandraratna
  • Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
    Patent number: 6720423
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification, are specific or selective agonists of RXR retinoid receptors.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: April 13, 2004
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Dehua Huang, Vidyasagar Vuligonda, Roshanta S. Chandraratna
  • Compounds having activity as inhibitors of cytochrome P450RAI
    Patent number: 6713647
    Abstract: Compounds having Formula 4 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: March 30, 2004
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Liming Wang, Roshantha A. Chandraratna
  • Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
    Publication number: 20030216570
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: April 30, 2002
    Publication date: November 20, 2003
    Inventors: Jayasree Vasudevan, Dehua Huang, Vidyasagar Vuligonda, Roshantha S. Chandraratna
  • 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
    Publication number: 20030207937
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: March 14, 2003
    Publication date: November 6, 2003
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Yang-Dar Yuan, Roshantha A. Chandraratna
  • 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity
    Publication number: 20030191181
    Abstract: Compounds of Formula 1 1
    Type: Application
    Filed: March 19, 2002
    Publication date: October 9, 2003
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Yang-Dar Yuan, Roshantha Chandraratna
  • Compounds having activity as inhibitors of cytochrome P450RAI
    Publication number: 20030186947
    Abstract: Compounds having Formula 4 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
    Type: Application
    Filed: February 11, 2003
    Publication date: October 2, 2003
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Liming Wang, Roshantha A. Chandraratna
  • 1-imidazolyl substituted tetrahydronaphthalene derivatives as inhibitors of eytochrome P450RAI
    Patent number: 6603019
    Abstract: Compounds having Formula 4 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: August 5, 2003
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Liming Wang, Roshantha A. Chandraratna